Apr 29, 2024, 14:18
Matthew Goetz: Abemacicib in high risk ER+/HER2 negative breast cancer
Matthew Goetz, Professor of Oncology and Pharmacology at Mayo Clinic, shared on LinkedIn:
“An important question in the adjuvant treatment of high risk ER+/HER2 negative breast cancer with Abemacicib:
Is the benefit of Abemacicib compromised in those that require dose reductions?
A secondary analysis of MonarchE suggests that reducing the dose to manage side effects did not alter efficacy.
Clinicians should utilize dose modifications when necessary to maximize adherence.”
Additional information.
Source: Matthew Goetz/LinkedIn
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Oct 23, 2024, 16:25
Oct 23, 2024, 16:03
Oct 23, 2024, 15:44
Oct 23, 2024, 15:44
Oct 23, 2024, 15:42
Oct 23, 2024, 15:15